Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBT251 vs Semaglutide in Type 2 Diabetes Mellitus (UNIGUIDE-2)
NCT07653477Phase 3Recruiting
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of UBT251 in type 2 diabetes mellitus (T2DM) (4 arms). Primary endpoint: Glycated Hemoglobin at 40 weeks. Started Sep 2026; status: recruiting.
02
Drugs
UBT251
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07653477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07653477.